newsfilter
← Latest News
GlobeNewswire·

Surface Oncology Appoints Carsten Brunn to Board of Directors

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D.,